Compare BKTI & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKTI | AKBA |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | United States | United States |
| Employees | 120 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.9M | 375.0M |
| IPO Year | 2000 | 2014 |
| Metric | BKTI | AKBA |
|---|---|---|
| Price | $83.50 | $1.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $74.00 | $4.67 |
| AVG Volume (30 Days) | 25.7K | ★ 4.7M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 52.89 | ★ 93.94 |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $74,094,000.00 | N/A |
| Revenue This Year | $6.57 | N/A |
| Revenue Next Year | $15.00 | N/A |
| P/E Ratio | $121.23 | ★ N/A |
| Revenue Growth | ★ 45.42 | N/A |
| 52 Week Low | $36.17 | $0.88 |
| 52 Week High | $104.55 | $4.08 |
| Indicator | BKTI | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 38.81 |
| Support Level | $73.47 | N/A |
| Resistance Level | $87.21 | $1.56 |
| Average True Range (ATR) | 4.76 | 0.09 |
| MACD | -1.30 | -0.03 |
| Stochastic Oscillator | 32.80 | 27.82 |
BK Technologies Corp is a holding company that, through BK Technologies, Inc., its operating subsidiary, provides public safety-grade communications products and services designed to make first responders safer and more efficient. All operating activities described herein are undertaken by its operating subsidiary. The Company has one reportable segment - Land Mobile Radio (LMR) Products and Solutions. The LMR segment provides radio devices that are hand-held (portable) or installed in vehicles (mobile) and operate on private radio systems that are P25 compliant. The Company derives revenue in North America and manages the business activities on a consolidated basis.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.